Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Q4 Dificid Sales In Line.
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.
Analyst, Alan Carr, said, "Optimer reported $11.0M in Dificid net sales in 4Q11, just above our $10.9M estimate. Gross sales of $12.2M were preannounced in January. Total revenues were $64.6M, boosted by recognition of a $53.6M milestone payment from collaborator Astellas. Diluted EPS of $0.28 was short of our $0.57 estimate because of higher than expected OpEx. Management is not yet providing Dificid sales or OpEx guidance. We continue to believe the stock is undervalued ($470M EV)."
Carr cuts FY12 EPS loss from (1.25) to (1.92) and FY13 EPS estimate from from $0.15 to $0.10.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.39 yesterday.
Analyst, Alan Carr, said, "Optimer reported $11.0M in Dificid net sales in 4Q11, just above our $10.9M estimate. Gross sales of $12.2M were preannounced in January. Total revenues were $64.6M, boosted by recognition of a $53.6M milestone payment from collaborator Astellas. Diluted EPS of $0.28 was short of our $0.57 estimate because of higher than expected OpEx. Management is not yet providing Dificid sales or OpEx guidance. We continue to believe the stock is undervalued ($470M EV)."
Carr cuts FY12 EPS loss from (1.25) to (1.92) and FY13 EPS estimate from from $0.15 to $0.10.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades Workday (WDAY) to Hold
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- MiMedx Group (MDXG) Reiterated at Overweight by Cantor Fitzgerald: Wound Care Market Stable
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
